Baird Downgrades Onyx Pharmaceuticals (ONXX) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Jefferies Cuts Onyx (ONXX) to Hold, Sees Limited Upside
August 2, 2013 8:25 AM EDTJefferies downgraded Onyx Pharmaceuticals (NASDAQ: ONXX) from Buy to Hold with a price target of $132.00 (from $104.00). Analyst Biren Amin sees limited upside from current levels.
"Given the M&A interest in ONXX we are downgrading to Hold on valuation and raising our PT... More
